Predictors for Post-treatment Biopsy Outcomes after Prostate Stereotactic Body Radiotherapy

Stereotactic body radiotherapy (SBRT) is a well-recognized treatment option for low- and intermediate-risk prostate cancer. Five-year prostate-specific antigen (PSA) relapse-free survival rates of approximately 90% have been reported for patients with low-risk and intermediate-risk disease when delivering SBRT prescription dose levels ranging from 34 –50 Gy [1-7]. Recent reports of prospective randomized trials comparing SBRT to moderate hypo-fractionated radiotherapy have demonstrated comparable disease-related outcomes for patients treated for low-risk and intermediate-risk prostate cancer [8,9].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research